HLHui Li

Hui Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hui Li has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Hai‐Di Wang

    State Key Laboratory of Natural Medicines Jiangsu Key Laboratory of Carcinogenesis and Intervention Key Laboratory of Drug Quality Control and Pharmacovigilance Ministry of Education Jiangsu Key Laboratory of Drug Design and Optimization China Pharmaceutical University 24 Tongjiaxiang Nanjing 210009 P. R. China

    1 shared publication
  • Hong‐Yu Chen

    State Key Laboratory of Natural Medicines Jiangsu Key Laboratory of Carcinogenesis and Intervention Key Laboratory of Drug Quality Control and Pharmacovigilance Ministry of Education Jiangsu Key Laboratory of Drug Design and Optimization China Pharmaceutical University 24 Tongjiaxiang Nanjing 210009 P. R. China

    1 shared publication
  • Hong‐Zheng Wang

    State Key Laboratory of Natural Medicines Jiangsu Key Laboratory of Carcinogenesis and Intervention Key Laboratory of Drug Quality Control and Pharmacovigilance Ministry of Education Jiangsu Key Laboratory of Drug Design and Optimization China Pharmaceutical University 24 Tongjiaxiang Nanjing 210009 P. R. China

    1 shared publication
  • Hui Hui

    State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of -Carcinogenesis and Intervention, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, China

    1 shared publication
  • Meng‐Yuan Zhu

    State Key Laboratory of Natural Medicines Jiangsu Key Laboratory of Carcinogenesis and Intervention Key Laboratory of Drug Quality Control and Pharmacovigilance Ministry of Education Jiangsu Key Laboratory of Drug Design and Optimization China Pharmaceutical University 24 Tongjiaxiang Nanjing 210009 P. R. China

    1 shared publication
  • Yong‐Jian Guo

    State Key Laboratory of Natural Medicines Jiangsu Key Laboratory of Carcinogenesis and Intervention Key Laboratory of Drug Quality Control and Pharmacovigilance Ministry of Education Jiangsu Key Laboratory of Drug Design and Optimization China Pharmaceutical University 24 Tongjiaxiang Nanjing 210009 P. R. China

    1 shared publication

Latest Publications

  • Open Access

    Activation of Lysosomal Retrograde Transport Triggers TPC1‐IP3R1 Ca 2+ Crosstalk at Lysosome‐ER MCSs Leading to Lethal Depleting of ER Calcium

    by Meng‐Yuan Zhu, Yong‐Jian Guo, Yu‐Qi Zhu, Hong‐Zheng Wang, Hai‐Di Wang, Hong‐Yu Chen, Yue‐Xin Jiang, Hui Li, Hui Hui

    Inter‐organellar signaling linkages in oncology are increasingly elucidated. However, the impact of lysosome‐endoplasmic reticulum (ER) interaction on tumor cell fate remains relatively unexplored. A novel interaction between lysosomes and the ER, mediated by the flavonoid LW‐213 through targeting LIMP2 (lysosomal integral membrane protein type 2)to activate a lysosomal repair pathway, is identified in acute myeloid leukemia (AML). This leads to activated RAB7A activity, enhancing lysosomal retrograde transport to the perinuclear region and increasing contact at lysosome‐ER membrane contact sites (MCSs). Close proximity of TPC1 to IP3R1 at these sites generates a concentrated calcium microdomain, triggering Ca 2+ ‐induced Ca 2+ release, which causes cytoplasmic calcium turbulence and two distinct calcium tides. This excessive calcium efflux depletes ER calcium stores, triggering lethal ER stress‐induced apoptosis. Interestingly, altering TPC1 expression levels in HeLa cells affected these calcium dynamics, replicating AML‐specific mechanisms when overexpressed. Subsequent studies using BALB/c xenograft models with wild‐type and LIMP2‐knockout THP1 cells, along with ICR mice toxicity models, confirmed LW‐213′s significant tumor growth inhibition with minimal toxicity. These findings underscore the potential of targeting lysosomal‐ER calcium crosstalk as an innovative approach to cancer treatment, highlighting the therapeutic promise of LW‐213 in managing tumor cell fate through modulating organellar interactions.